文献速递头颈部肿瘤放疗

有利风险HPV相关口咽癌患者降低强度放化疗后的生活质量

Quality of Life for Patients With Favorable-Risk HPV-Associated Oropharyngeal Cancer After De-intensified Chemoradiotherapy.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2018-11-02

两项前瞻性2期试验纳入154例HPV相关口咽癌患者,接受同步放疗60 Gy与每周顺铂30 mg/m2降低强度放化疗,126例随访至少1年(中位随访25个月),整体生活质量与多数症状在3至6个月恢复基线,吞咽功能至2年恢复基线。

要点

  • 整体生活质量、功能指标和多数症状在治疗后3至6个月恢复至基线水平
  • 吞咽功能(Eating Assessment Tool-10评分)至2年恢复至基线功能
  • 口干、唾液黏稠和味觉/感觉未恢复至基线,但1至2年间持续改善

核心结论

  • 在HPV相关口咽癌中采用降低强度放化疗获得良好的患者报告结局,生活质量早期恢复,口干和吞咽困难在治疗后1年以上持续改善。

研究设计与样本

  • 研究纳入2项前瞻性2期降低强度放化疗试验中HPV相关口咽癌且随访至少1年的患者。
  • 治疗方案为同步放疗60 Gy与化疗(每周顺铂30 mg/m2)。
  • 共154例患者入组,126例纳入分析,中位随访25个月。
  • 使用欧洲癌症研究与治疗组织生活质量问卷-C30、头颈癌模块-35和Eating Assessment Tool-10在治疗前及此后定期评估生活质量和症状。

主要发现

  • 整体生活质量、功能指标和多数个体症状在治疗后3至6个月恢复至基线水平。
  • 吞咽(Eating Assessment Tool-10评分)至2年恢复至基线功能。
  • 口干、唾液黏稠和味觉/感觉未恢复至基线水平。
  • 从1年至2年,口干评分(55 vs 48)、唾液黏稠评分(35 vs 27)和感觉评分(24 vs 20)持续改善。
  • 多因素分析显示单侧放疗与吞咽和唾液黏稠恢复至基线水平相关。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Oropharynx cancers associated with human papillomavirus (HPV) have a favorable prognosis, but current treatment approaches carry significant long-term morbidity. Strategies to de-intensify treatment in this population are under investigation, but the impact of these approaches on quality of life (QOL) is not well understood. We present patient-reported outcomes from 2 prospective studies examining de-intensified chemoradiotherapy. METHODS AND MATERIALS: This study included patients enrolled in 2 prospective phase 2 trials of de-intensified chemoradiotherapy in patients with HPV-associated oropharynx cancer who had at least 1 year of follow-up. Treatment included concurrent radiation therapy (60 Gy) and chemotherapy (weekly cisplatin, 30 mg/m2). Patients reported QOL and symptoms using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-C30, the European Organisation for Research and Treatment of Cancer Head and Neck Cancer Module-35, and the Eating Assessment Tool-10 instruments before treatment and at regular intervals thereafter. Changes in QOL and individual symptoms were examined over time, and multivariate analysis was used to identify clinical factors associated with recovery to baseline symptom levels. RESULTS: Of the 154 patients enrolled, 126 patients had at least 1 year of follow-up and were included in this study (median follow-up, 25 months). Global QOL, functional indices, and most individual symptoms returned to baseline 3 to 6 months after treatment. Swallowing (Eating Assessment Tool-10 score) returned to baseline function by 2 years, but dry mouth, sticky saliva, and taste/senses did not return to baseline levels. However, from 1 to 2 years, continued improvement occurred in dry mouth score (55 vs 48), sticky saliva score (35 vs 27), and senses score (24 vs 20). On multivariate analysis, unilateral radiation therapy was associated with returning to baseline level of swallowing and sticky saliva. CONCLUSIONS: The use of de-intensified chemoradiotherapy in HPV-associated oropharynx cancer led to favorable patient-reported outcomes, with early recovery of QOL and continued improvement of xerostomia and dysphagia beyond 1-year posttreatment.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Pearlstein KA, Wang K, Amdur RJ, et al. Quality of Life for Patients With Favorable-Risk HPV-Associated Oropharyngeal Cancer After De-intensified Chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2018. PMID: 30395903. doi:10.1016/j.ijrobp.2018.10.033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。